bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-3418

Order Name:
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
Useful For:
MI Tumor Seek (test by NGS), plus PD-L1, plus MMR testing.

PD-1 (test by IHC) is an immunosuppressive protein molecule that is upregulated on activated T-cells and other immune cells. It is activated by binding to its ligand, PD-L1, an action that results in intracellular responses that reduce T-cell activation. Reports of aberrant PD-L1 expression in cancer cells have spurred the development of PD-1 and PD-L1 inhibitors. The U.S. Food and Drug Administration (FDA) recently approved an anti-PD-1 therapy, pembrolizumab (Keytruda), for the treatment of advanced or unresectable melanoma. Another anti-PD-1 agent, nivolumab, was recently approved in Japan for the treatment of unresectable melanoma.

MMR genes create a system for recognizing and repairing mistakes that arise during DNA replication. If the MMR genes themselves become damaged or mutated, they will not work properly and the mistakes made during replication will not be repaired. This leaves the cell vulnerable and unhealthy. Cells without normal MMR genes can develop more and more mistakes with each new copy, resulting in a normal healthy cell losing the ability to stop dividing, or growing, once it has appropriately replaced itself. The ability to stop dividing, or growing, is what causes a colon cell to become cancerous. 
 
Methodology:
Next-generation sequencing (NGS)
 
Test List In Profile:
All Biomarker Analysis includes:
DNA Mutation, Copy Number Alterations, Insertions/Deletions    
Genomic Signatures: MSI, TMB
RNA Fusion Analysis
IHC: PD-L1, MMR
 
AliasesName:
Comprehensive Genomic Profiling, Tissue
 
 
 
Test Code:
090-71-3418

Order Name:
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
Collection Specimen Or Container:
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Specimen Testing Type:
NGS: FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores).
IHC: 1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test
 
Sub Mission Container:
Specimen collection kit
 
Rejection Criteria:
Specimen was insufficient for testing (Low cellularity, Low tumor purity, DNA highly fragmentation, Low of RNA quality)
 
 
 
Test Code:
090-71-3418

Order Name:
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
Method detail:
Next-generation sequencing (NGS)
 
Schedule:
N/A **Sent out to Caris, USA
 
Turnaround Time:
Received specimen to report 20-30 days (Slide received to report)
 
Performing Location:
Caris Life Sciences, USA
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-3418

Order Name:
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
 
Reference Value:
An interpretive report will be provided.
 
Clinical Reference:
www.carislifesciences.com (Retrieved: 25 Jun 2020)